Pulmonary arterial hypertension associated with interferon beta treatment for multiple sclerosis: a case report

A 23-year-old woman with multiple sclerosis developed respiratory symptoms 3 years after introduction of interferon beta-1b. The diagnosis of pulmonary arterial hypertension (PAH) was established. The patient partially responded to sildenafil and bosetan treatment. This is the first report of PAH, a...

Full description

Saved in:
Bibliographic Details
Published in:Multiple sclerosis 2009-07, Vol.15 (7), p.885-886
Main Authors: Ledinek, AH, Jazbec, SŠ, Drinovec, I, Rot, U
Format: Article
Language:English
Subjects:
Antihypertensive Agents - therapeutic use
Biological and medical sciences
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
Drug Therapy, Combination
Female
Hemodynamics - drug effects
Humans
Hypertension, Pulmonary - chemically induced
Hypertension, Pulmonary - drug therapy
Hypertension, Pulmonary - physiopathology
Immunologic Factors - adverse effects
Interferon beta-1b
Interferon-beta - adverse effects
Medical sciences
Multiple Sclerosis - drug therapy
Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis
Neurology
Piperazines - therapeutic use
Pulmonary Artery - drug effects
Pulmonary Artery - physiopathology
Purines - therapeutic use
Sildenafil Citrate
Sulfonamides - therapeutic use
Sulfones - therapeutic use
Treatment Outcome
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A 23-year-old woman with multiple sclerosis developed respiratory symptoms 3 years after introduction of interferon beta-1b. The diagnosis of pulmonary arterial hypertension (PAH) was established. The patient partially responded to sildenafil and bosetan treatment. This is the first report of PAH, associated with interferon beta therapy. As shown in experimental models, interferon treatment can induce PAH by stimulation of thromboxane cascade and secretion of various inflammatory mediators.
ISSN:1352-4585
1477-0970
DOI:10.1177/1352458509104593